Adagene Inc. SEC filings ADAG
Adagene Inc. has 191 filings in SEC EDGAR's recent list, going back to Sep 22, 2020. Its latest annual report, Form 20-F, was filed on Apr 1, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Sep 25, 2026. The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Sep 25, 2026 | Sep 25, 2026 |
| 6-K | Current report (foreign issuer) | Sep 22, 2026 | Sep 22, 2026 |
| 6-K | Current report (foreign issuer) | Sep 10, 2026 | Sep 10, 2026 |
| 6-K | Current report (foreign issuer) | Sep 9, 2026 | Sep 9, 2026 |
| 6-K | Current report (foreign issuer) | Aug 12, 2026 | Jun 30, 2026 |
| 6-K | Current report (foreign issuer) | Jul 6, 2026 | Jul 6, 2026 |
| 6-K | Current report (foreign issuer) | Apr 17, 2026 | Apr 17, 2026 |
| 6-K | Current report (foreign issuer) | Apr 2, 2026 | Apr 2, 2026 |
| 6-K | Current report (foreign issuer) | Apr 2, 2026 | Apr 2, 2026 |
| 6-K | Current report (foreign issuer) | Apr 1, 2026 | Apr 1, 2026 |
| 6-K | Current report (foreign issuer) | Jan 23, 2026 | Jan 23, 2026 |
| 6-K | Current report (foreign issuer) | Nov 13, 2025 | Nov 13, 2025 |
| 6-K | Current report (foreign issuer) | Aug 12, 2025 | Jun 30, 2025 |
| 6-K | Current report (foreign issuer) | Jul 15, 2025 | Jul 15, 2025 |
| 6-K | Current report (foreign issuer) | Jul 1, 2025 | Jul 1, 2025 |
| 6-K | Current report (foreign issuer) | May 22, 2025 | May 22, 2025 |
| 6-K | Current report (foreign issuer) | Mar 24, 2025 | Mar 24, 2025 |
| 6-K | Current report (foreign issuer) | Jan 27, 2025 | Jan 27, 2025 |
| 6-K/A | Form 6-k/a | Nov 7, 2024 | Sep 16, 2024 |
| 6-K/A | Form 6-k/a | Nov 7, 2024 | Jul 25, 2024 |
| 6-K | Current report (foreign issuer) | Nov 7, 2024 | Nov 7, 2024 |
| 6-K | Current report (foreign issuer) | Sep 16, 2024 | Sep 16, 2024 |
| 6-K | Current report (foreign issuer) | Jul 25, 2024 | Jun 30, 2024 |
| 6-K | Current report (foreign issuer) | Mar 29, 2024 | Mar 29, 2024 |
| 6-K | Current report (foreign issuer) | Mar 29, 2024 | Mar 29, 2024 |
| 6-K | Current report (foreign issuer) | Feb 9, 2024 | Feb 9, 2024 |
| 6-K | Current report (foreign issuer) | Jan 16, 2024 | Jan 16, 2024 |
| 6-K | Current report (foreign issuer) | Nov 3, 2023 | Nov 3, 2023 |
| 6-K | Current report (foreign issuer) | Sep 29, 2023 | Sep 29, 2023 |
| 6-K | Current report (foreign issuer) | Aug 31, 2023 | Aug 31, 2023 |
| 6-K | Current report (foreign issuer) | Jul 7, 2023 | Jul 7, 2023 |
| 6-K | Current report (foreign issuer) | May 4, 2023 | May 4, 2023 |
| 6-K | Current report (foreign issuer) | Apr 28, 2023 | Apr 28, 2023 |
| 6-K | Current report (foreign issuer) | Apr 18, 2023 | Apr 18, 2023 |
| 6-K | Current report (foreign issuer) | Mar 28, 2023 | Mar 28, 2023 |
| 6-K | Current report (foreign issuer) | Jan 9, 2023 | Jan 9, 2023 |
| 6-K | Current report (foreign issuer) | Dec 16, 2022 | Dec 16, 2022 |
| 6-K | Current report (foreign issuer) | Nov 21, 2022 | Nov 21, 2022 |
| 6-K | Current report (foreign issuer) | Sep 12, 2022 | Sep 12, 2022 |
| 6-K | Current report (foreign issuer) | Aug 31, 2022 | Aug 31, 2022 |
| 6-K | Current report (foreign issuer) | Jun 29, 2022 | Jun 29, 2022 |
| 6-K | Current report (foreign issuer) | May 26, 2022 | May 26, 2022 |
| 6-K | Current report (foreign issuer) | Apr 8, 2022 | Apr 8, 2022 |
| 6-K | Current report (foreign issuer) | Mar 31, 2022 | Mar 31, 2022 |
| 6-K | Current report (foreign issuer) | Mar 16, 2022 | Mar 16, 2022 |
| 6-K | Current report (foreign issuer) | Mar 9, 2022 | Mar 9, 2022 |
| 6-K | Current report (foreign issuer) | Mar 2, 2022 | Mar 2, 2022 |
| 6-K | Current report (foreign issuer) | Feb 3, 2022 | Feb 3, 2022 |
| 6-K | Current report (foreign issuer) | Jan 27, 2022 | Jan 27, 2022 |
| 6-K | Current report (foreign issuer) | Jan 19, 2022 | Jan 19, 2022 |
| 6-K | Current report (foreign issuer) | Jan 13, 2022 | Jan 13, 2022 |
| 6-K | Current report (foreign issuer) | Jan 12, 2022 | Jan 12, 2022 |
| 6-K | Current report (foreign issuer) | Dec 22, 2021 | Dec 22, 2021 |
| 6-K | Current report (foreign issuer) | Dec 14, 2021 | Dec 14, 2021 |
| 6-K | Current report (foreign issuer) | Dec 7, 2021 | Dec 7, 2021 |
| 6-K | Current report (foreign issuer) | Dec 6, 2021 | Dec 6, 2021 |
| 6-K | Current report (foreign issuer) | Nov 29, 2021 | Nov 29, 2021 |
| 6-K | Current report (foreign issuer) | Nov 23, 2021 | Nov 23, 2021 |
| 6-K | Current report (foreign issuer) | Nov 4, 2021 | Nov 4, 2021 |
| 6-K | Current report (foreign issuer) | Oct 27, 2021 | Oct 27, 2021 |
| 6-K | Current report (foreign issuer) | Aug 26, 2021 | Aug 26, 2021 |
| 6-K | Current report (foreign issuer) | Aug 19, 2021 | Aug 19, 2021 |
| 6-K | Current report (foreign issuer) | Aug 12, 2021 | Aug 12, 2021 |
| 6-K | Current report (foreign issuer) | Jul 22, 2021 | Jul 22, 2021 |
| 6-K | Current report (foreign issuer) | Jul 7, 2021 | Jul 7, 2021 |
| 6-K | Current report (foreign issuer) | May 19, 2021 | May 19, 2021 |
| 6-K | Current report (foreign issuer) | Apr 13, 2021 | Apr 30, 2021 |
| 6-K | Current report (foreign issuer) | Mar 31, 2021 | Mar 31, 2021 |
| 6-K | Current report (foreign issuer) | Mar 29, 2021 | Mar 31, 2021 |
| 6-K | Current report (foreign issuer) | Mar 16, 2021 | Mar 31, 2021 |
Showing 70 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ADAG (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Cayman Islands
- Headquarters
- Jiangsu, China
- SEC filer status
- Accelerated filer, Emerging growth company
- SEC CIK
- 1818838
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.